Anaptysbio, INC 8-K filings

NASDAQ

12 Jun 2024

ANAB

8-K: AnaptysBio Amends 2017 Equity Incentive Plan and Holds Annual Meeting

AnaptysBio held its 2024 Annual Meeting of Stockholders, approving the election of directors, ratification of auditors, executive compensation, and an amendment to the 2017 Equity Incentive Plan.

NASDAQ

9 May 2024

ANAB

Anaptysbio, INC

8-K: AnaptysBio Reports Q1 2024 Financial Results and Provides Clinical Pipeline Update

AnaptysBio announced its first quarter 2024 financial results, highlighted by a $50 million royalty monetization and progress in its clinical trials.

NASDAQ

11 Mar 2024

ANAB

Anaptysbio, INC

8-K: AnaptysBio Reports Year-End 2023 Financial Results and Provides Clinical Pipeline Update

AnaptysBio announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical trials and pipeline development.